Safety of gadoteridol injection: U.S. clinical trial experience
- 1 January 1995
- journal article
- clinical trial
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 5 (1), 17-25
- https://doi.org/10.1002/jmri.1880050106
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Efficacy evaluation of gadoteridol for MR angiography of intracranial vascular lesionsJournal of Magnetic Resonance Imaging, 1994
- Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease.Radiology, 1993
- Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease.Radiology, 1991
- Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine.Radiology, 1991
- Evaluation of the Safety and Efficacy of Gadoteridol Injection (a low osmolal magnetic resonance contrast agent): Clinical Trials ReportInvestigative Radiology, 1991
- Pituitary adenoma: correlation of half-dose gadolinium-enhanced MR imaging with surgical findings in 26 patients.Radiology, 1991
- MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.Radiology, 1991
- Synthesis of nonionic gadolinium chelates useful as contrast agents for magnetic resonance imaging: 1,4,7-tris(carboxymethyl)-10-substituted-1,4,7,10-tetraazacyclododecanes and their corresponding gadolinium chelatesInorganic Chemistry, 1991
- Gd-HP-DO3A in clinical MR imaging of the brain.Radiology, 1990
- Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.Radiology, 1990